Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.74 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.74 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.74 |
| ▸ | BLM | P54132 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 1/20 | 0.74 |
| ▸ | IDO1 | P14902 | 1/20 | 0.74 |
| ▸ | SPR | P35270 | 1/20 | 0.74 |
| ▸ | NQO2 | P16083 | 3/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.69 |
| ▸ | MPO | P05164 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7022024 | 0.94 | MTNR1A (0.66) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL4498391 | 0.91 | MTNR1A (0.72) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL31543734 | 0.91 | MTNR1A (0.72) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL14493805 | 0.91 | MTNR1A (0.72) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL31543657 | 0.90 | MTNR1A (0.73) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL31543642 | 0.87 | MTNR1A (0.67) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL31543683 | 0.87 | MTNR1A (0.67) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL31543620 | 0.87 | MTNR1A (0.67) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL10747115 | 0.86 | MTNR1A (0.62) | MTNR1AMTNR1BCYP1A2NOTUMBLM | |
| SCHEMBL9800344 | 0.86 | MTNR1A (0.62) | MTNR1AMTNR1BCYP1A2NOTUMBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1038863-B1 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | claimed |
| US-20020035114-A1 | Substituted dimeric compounds | LESIEUR DANIEL (FR) | 2002-03-21 | — | — | US | claimed |
| EP-1038863-A2 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | claimed |
| US-6635650-B2 | Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders | LES LABORATOIRES SERVIER (FR) | 2003-10-21 | — | — | US | disclosed |
| US-20020035114-A1 | Substituted dimeric compounds | LESIEUR DANIEL (FR) | 2002-03-21 | — | — | US | disclosed |
| US-6319930-B1 | CONTAINING FUSED AROMATIC CARBO- OR HETEROCYCLIC RINGS AND AMIDE, THIOAMIDE, UREA OR THIOUREA GROUPS; USEFUL IN TREATING OR IN PREVENTING MELATONINERGIC DISORDERS. | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | disclosed |
| JP-2000319242-A | NEW SUBSTITUTED DIMER COMPOUND, METHOD FOR PRODUCING THE SAME AND MEDICINAL COMPOSITION CONTAINING THE SAME | ADIR | 2000-11-21 | — | — | JP | disclosed |
| EP-1038863-A2 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | disclosed |
| EP-1038863-A2 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035114-A1 | Substituted dimeric compounds | NR0B2, NR0B1, NR2C2 | MTNR1A 4/4885MTNR1B 5/4885CYP1A2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.